The lucrative era of expanding dialysis clinics is ending. Regulatory pressures and soaring labor costs are forcing a permanent shift toward home-based care and early disease management. Providers must now prioritize patient outcomes and remote technologies over treatment volume to survive.
Chicago, Feb. 02, 2026 (GLOBE NEWSWIRE) — The global end stage renal disease market size was valued at USD 152.64 billion in 2025 and is projected to hit the market valuation of USD 573.86 billion by 2035 at a CAGR of 14.16% during the forecast period 2026–2035.
Demographic shifts are creating substantial pressure on the end stage renal disease market infrastructure. Data from the USRDS 2024 Annual Data Report confirms that a staggering 273,041 individuals are currently living with a functioning kidney transplant. Such volume is compounded by an aggressive waitlist trajectory. Over 30,000 dialysis patients were added to the transplant waitlist in 2024 alone. UNOS data highlights a record-breaking operational throughput with 48,149 total organ transplants performed in the U.S. throughout 2024. Kidney-specific procedures accounted for 27,759 of these successful operations.
Request Sample Pages: https://www.astuteanalytica.com/request-sample/end-stage-renal-disease-market
The donor landscape is simultaneously evolving to meet this critical need. Deceased donor transplants surpassed a major milestone by reaching 41,119 in 2024. Living donor kidney transplants also saw a significant resurgence. Surgeons completed 6,418 living donor procedures in 2024. The demographic profile of these donors is expanding as well. Physicians successfully utilized organs from 475 living kidney donors aged 65 or older in 2024. These figures signal a robust expansion in procedural capacity and patient eligibility.
Key Findings Shaping the End Stage Renal Disease Market
- Asia Pacific holds lion’s share of nearly 36.95% and is set to continue being the leader in the market.
- Based on Treatment, dialysis emerged as the most sought after treatment as it accounts for the largest 81.23% share in 2025.
- Based on Treatment, transplant is estimated to grow at the robust CAGR of 15.38% during the forecast period.
Asia Pacific Commands 36.95% Share Amidst Escalating Diabetic Nephropathy Crisis
The region’s unassailable position in the end stage renal disease market is underpinned by a worsening metabolic health epidemic that feeds the renal failure pipeline. The IDF Diabetes Atlas 2025 reports that 215 million adults now live with diabetes in the Western Pacific, creating a massive reservoir of patients susceptible to kidney complications. Governments are responding with rapid infrastructure scaling; China’s National Health Commission achieved a critical milestone where over 90% of county-level hospitals.
This localized accessibility is financially supported by regional manufacturing giants like Nipro Corporation, which posted a trailing 12-month revenue of $4.23 billion ending March 2025, highlighting the profitability of the Asian supply chain. With recent data estimating China alone manages 152 million chronic kidney disease cases, the region possesses the sheer patient density required to sustain its revenue leadership indefinitely.
Dialysis Secures 81.23% Market Share Via Home Modality And Reimbursement Hikes
The dialysis segment retains its massive majority in the End stage renal disease market by successfully pivoting toward value-based home care and securing federal payment stability. In the United States, the Centers for Medicare & Medicaid Services solidified provider economics by finalizing the ESRD Prospective Payment System base rate at $273.82 for 2025, ensuring centers can manage inflationary pressures.
Simultaneously, clinical delivery models are transforming; industry leader DaVita Inc. revealed that 15% of their total patients utilized home-based modalities in their 2025 community care reports, validating the shift toward lower-cost treatment settings.
The segment’s scale is further evidenced by global demand, with analysts projecting the total dialysis patient population reached approximately 4.9 million by the end of 2025. Additionally, the operational integration of oral-only phosphate binders into the bundled payment system effective January 1, 2025, has streamlined revenue cycle management for major providers.
Transplant Segment in the End Stage Renal Disease Market Set For CAGR of 15.38% Through Living Donor Resilience
While deceased donation faces logistical hurdles, the transplant segment is projected to achieve the fastest growth due to a surge in living donation and allocation policy reforms. Data from the Kidney Transplant Collaborative indicates that living donor kidney transplants rose to 6,521 procedures in 2025, compensating for structural fluctuations in deceased donor availability. This resilience is critical for the End stage renal disease market, as the 103,223 candidates remaining on the national waitlist in 2025 drive an urgent demand for alternative solutions.
The sector’s momentum is also buoyed by the historic baseline set in the previous year, where over 48,149 total organ transplants were performed, signaling robust system capacity. Consequently, the market is aggressively adopting advanced preservation technologies to maximize the utilization of the 28,377 kidney transplants performed annually, ensuring this curative option expands faster than maintenance dialysis over the next decade.
Federal Policy Shifts Elevate Reimbursement Baselines For Providers
Governmental pricing strategies for 2025 reflect a recognition of rising operational costs within the End stage renal disease market. The Centers for Medicare & Medicaid Services finalized the ESRD PPS base rate for 2025 at USD 273.82. Such a valuation represents a base rate increase of USD 2.80 over the prior year. Additionally, the finalized market basket update for dialysis facilities stands at 2.2%. CMS projects that total payments to all ESRD facilities will consequently rise by 2.7% in 2025.
Facility-specific adjustments reveal a distinct advantage for institutional providers. Hospital-based dialysis facilities are set to realize a payment increase of 4.5% in 2025. Freestanding facilities will see a more moderate 2.6% increase in total payments. To maintain fiscal balance, the wage index budget-neutrality adjustment factor was strictly set at 0.988600. These calibrated updates ensure that providers can sustain operations while navigating inflationary pressures inherent to the healthcare supply chain.
Targeted Payment Adjustments Reshape Pediatric and Low Volume Care
Regulators are applying granular financial levers to protect vulnerable populations in the End stage renal disease market. For pediatric care, the Fixed Dollar Loss (FDL) amount increased significantly to USD 234.26 in 2025. In contrast, the adult FDL decreased to USD 45.41. Outlier services also saw revised caps. The Medicare Allowable Payment (MAP) for pediatric outlier services rose to USD 59.60. Meanwhile, the adult MAP was finalized at USD 31.02. Such disparity highlights a strategic focus on subsidizing high-cost pediatric treatments.
Rural and smaller facilities will benefit from tiered support structures. CMS established a Tier 1 low-volume payment adjustment of 28.9% for facilities performing fewer than 3,000 treatments. A Tier 2 adjustment of 18.3% applies to facilities performing between 3,000 and 3,999 treatments. Furthermore, the Acute Kidney Injury (AKI) dialysis payment rate was aligned perfectly with the standard base rate at USD 273.82. These adjustments provide a necessary safety net for critical access providers.
Leading Competitors in the End Stage Renal Disease Market Consolidate Networks While Optimizing Global Operations
Market dominance remains concentrated among key giants who are aggressively optimizing their footprints. DaVita provided a massive 7,350,784 dialysis treatments in the U.S. during Q3 2024. The company served approximately 265,400 patients domestically as of that same period. Their infrastructure includes a vast network of 3,113 outpatient dialysis centers globally. Of these locations, 2,660 centers operate within the United States. International operations remain robust with 453 centers across 13 countries.
Operational efficiency is a primary focus for these major entities in the end stage renal disease market. For instance, DaVita consolidated its network by closing 15 U.S. dialysis centers in Q3 2024. The firm simultaneously opened 3 new centers. Financial health remains strong, with DaVita reaffirming 2024 adjusted operating income guidance between USD 1.91 billion and USD 2.01 billion. Competitor Fresenius Medical Care treated 308,216 patients globally as of Q3 2024. Fresenius managed a global network of 3,732 clinics. Their workforce scale is immense, with 113,079 employees reported in Q3 2024.
Pharmacological Breakthroughs and Investment Capital Fuel Market Optimism
Clinical innovation is altering the long-term outlook for the End stage renal disease market. The landmark FLOW trial demonstrated that Semaglutide reduced the risk of major kidney disease events by 24%. Researchers enrolled 3,533 participants with Type 2 diabetes and chronic kidney disease for this study. The drug resulted in a 1.16 mL/min/1.73 m² slower annual decline in eGFR compared to placebo. MACE events dropped by 18%. Most notably, all-cause mortality was reduced by 20% among participants.
Investor confidence in new care models is parallelly surging. Strive Health secured USD 300 million in Series D equity financing in 2025. The company also secured USD 250 million in debt financing. Following this round, Strive Health reached a valuation of USD 1.8 billion. Their network expanded to include 6,500 provider partners by 2025. Such capital injection validates the shift toward value-based kidney care solutions.
Managed Care Dominance Alters The Financial Trajectory Of Treatment in end Stage Renal Disease Market
The payer landscape is witnessing a historic shift toward managed care dominance. Medicare Advantage (MA) spending on ESRD surpassed Fee-For-Service (FFS) for the first time, reaching USD 27.7 billion. Total Medicare FFS spending on ESRD beneficiaries trailed at USD 28.9 billion. The per-person-per-year (PPPY) cost for ESRD patients in Medicare Advantage hit USD 94,356. In comparison, the PPPY cost for FFS Medicare patients was significantly lower at USD 68,786.
Cost variance between treatment modalities continues to drive payer strategies in the end stage renal disease market. In-center hemodialysis costs remained 18% higher than peritoneal dialysis costs on a per-person basis. Value-based entities are capturing massive segments of this spend. Somatus reported having USD 14 billion in healthcare costs under management in July 2025. Similarly, Strive Health reported managing nearly USD 5 billion of annual medical spend as of late 2025. These figures confirm that managed care is the new financial engine of the End stage renal disease market.
Home Dialysis Innovation Accelerates Through New Tech Clearances
Technological advancements are dismantling barriers to home-based care adoption. Quanta Dialysis Technologies received FDA 510(k) clearance for its system’s home use on November 4, 2024. The Quanta system offers a unique dialysate flow rate of 500 mL/min in a home setting. Safety protocols are also being tightened. Outset Medical initiated a recall of 879 Tablo Hemodialysis Systems in 2024 due to leaching. The FDA subsequently established a conditioning protocol of 336 hours for these devices.
Adoption metrics indicate a successful transition to the home environment. Somatus achieved a 48% higher home dialysis start rate in 2024 compared to the USRDS national benchmark. Monogram Health reported 18% of its patients initiating dialysis at home. This figure surpasses the 13.3% national average. Long-term trends underscore this shift. USRDS 2024 data notes that home hemodialysis prevalence has increased by 60% over the reported decade. The End stage renal disease market is clearly pivoting toward decentralized care.
Xenotransplantation And Improved Clinical Outcomes Redefine Survival Possibilities
Radical scientific achievements in 2024 and 2025 are pushing the boundaries of possibility. The first genetically modified pig kidney transplant into a living human occurred in March 2024. A second xenotransplant recipient maintained kidney function for 130 days before removal in 2025. Traditional transplant hubs are also increasing throughput. Erie County Medical Center performed 143 kidney transplants in 2024. These milestones represent a potential future solution to organ shortages.
Care management platforms are simultaneously improving survival rates for existing patients. Somatus served over 500,000 patients across all 50 states as of July 2025. Their integrated model is yielding tangible clinical success. Somatus achieved a 20% lower mortality rate in its dialysis centers compared to the CMS benchmark. Such outcomes prove that integrated care models are essential for the evolution of the End stage renal disease market.
Diagnostic Precision and Sustainability Goals Transform Operational Standards
Early detection and environmental governance are becoming central to market valuation. Renalytix reported FY2024 revenue of USD 2.3 million. The diagnostic firm saw a 33% quarter-over-quarter increase in test orders in Q3 2024. Medicare set the reimbursement rate for the KidneyIntelX.dkd test at USD 950. Approximately 850 doctors had ordered the test by early 2025. Cumulative test orders reached 15,000 by March 2025.
Sustainability initiatives are equally aggressive among major providers. DaVita reported saving 75 million gallons of water through efficiency projects in 2024. The company achieved a 73% reduction in operational emissions against its baseline. DaVita is on track for 100% renewable energy usage by 2025. Fresenius Medical Care implemented projects targeting annual water savings of 340,000 cubic meters. Specific upgrades at Fresenius’s Beijing site saved 20,000 cubic meters of water in 2024. Green operations are now a standard expectation in the End stage renal disease market.
Need a Customized Version? Request It Now: https://www.astuteanalytica.com/ask-for-customization/end-stage-renal-disease-market
End Stage Renal Disease Market Major Players:
- Cantel Medical
- Asahi Kasei Medical Co., Ltd.
- B. Braun Melsungen AG
- Baxter International, Inc.
- AngioDynamics, Inc.
- Becton Dickinson and Company
- DaVita Inc.
- U.S. Renal Care, Inc.
- JMS Co. Ltd.
- Medtronic Plc
- Nikkiso Co., Ltd.
- Fresenius Medical Care AG & Co. KGaA
- Nipro Corporation
- Teleflex Incorporated
- Toray Industries Inc.
Key Market Segmentation:
By Treatment
- Transplant
- Dialysis
By Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Need a Detailed Walkthrough of the Report? Request a Live Session: https://www.astuteanalytica.com/report-walkthrough/end-stage-renal-disease-market
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: [email protected]
Website: https://www.astuteanalytica.com/
Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: [email protected] Website: https://www.astuteanalytica.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.